---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031448"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:40:46.315647+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated

## Summary
- Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.
- Net loss for 2023 was $101.9M ($1.40 per share) vs $68.2M ($1.01 per share) in 2022.
- R&D expenses for 2023 increased 68% to $85.7M, driven by PALIZADE, PORTOLA trials and milestone payment to Onyx.
- Restructuring and impairment charges of $6.2M in Q4 2023 from employee termination benefits and asset impairment.
- PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) enrolling; topline data expected mid-2026 and mid-2025 respectively.

## SEC filing metadata
- accession: 0000950170-24-031448
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/0000950170-24-031448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/kzr-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031448
- JSON: https://secwatch.observer/filing/0000950170-24-031448.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031448.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $7.0 million.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $7.0 million
  - Result: reported results
  source text: Revenue for the year of 2023 was $7.0 million resulting from the upfront payment under the collaboration and license agreement with Everest Medicines.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/0000950170-24-031448-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.